

5 April 2020

Dear Equity Client

GLOBAL EQUITIES – 1st Quarter 2020

World equity markets were hit by the unexpected global COVID-19 pandemic. The MSCI World Index (including Emerging Markets and dividends) dropped -21.4% (US\$ terms, -15.9 % UK£ terms) over the quarter.

With China taking strong action to contain the virus and delivering positive results in this context, most observers initially underestimated the pace and the scale of the potential infections globally. Most governments were ill prepared for the necessary actions and treatments, with the result that most countries had to lock down social interactions, with immensely negative economic effects. Along with this, following the drop in oil demand and the oil price, negotiations between Russia and Saudi Arabia to limit supplies failed, causing a further collapse in the oil price. This triggered spikes in the cost of higher yielding corporate debt and a further collapse in investor confidence. COVID-19 is a truly 'black swan' event, triggering a deep global recession and pushing equity markets officially into bear market territory.

Because this crisis is about human health and life, all governments and central banks are able to offer almost limitless financial support through various aggressive monetary and fiscal measures. The availability of funds is currently almost of no object to save businesses and feed the nation during the various lockdown measures (although this is logistically difficult to manage). This support aspect is critical and very different from all previous economic crises.

Whilst China is currently in a slow recovery phase, the rest of the world is still in various stages of economic lockdowns. It is absolutely essential to properly contain the virus to lower risk of another pandemic following this one, and we can expect to eventually return to a different social and economic environment than what we were used to. Hopefully a cure for the virus can later be found, but it is too early to predict a timeline on that. In the interim, we expect market sentiment to be guided by new infection rates to quite some degree. A solution to the oil impasse would also be helpful.

The economic outlook is now particularly clouded. It depends clearly on the success in containing the virus and getting economies restarted. No-one can put a timeline with conviction on this either. We, though, also do believe that the world has made co-ordinated progress in understanding how to deal with this monster, the necessary financial support is at hand, that scientists will later develop a successful vaccine and that the world economy will recover.

Whilst this is a painful experience for us to report on, we are also confident that we have the right investment philosophy of owning outstanding quality businesses with a long-term orientation. We have, therefore, not been caught in the specific large casualties of COVID-19 and do not see reason for any material changes in the portfolio. We are considering some of the great new quality opportunities.

We are grateful for all your support.

With best wishes for good health.



Gerrit Smit
Partner – Head of Equity Management

*Our thoughts are with everyone affected
by COVID-19, be it directly or indirectly.*

RISK DISCLOSURE

1. This communication has been prepared for information only and is not intended for onward distribution. It is neither an offer to sell, nor a solicitation to buy, any investments or services. This communication does not constitute a personal recommendation and does not take into account the individual financial circumstances, needs or objectives of the recipients.
2. All investments risk the loss of capital. No guarantee or representation is made that the funds will achieve their investment objective.
3. The value of investments may go down as well as up and, for products designed to return income, the distributions can also go down or up and you may not receive back the full value of your initial investment.
4. Past performance should not be used as a guide to future performance.
5. The advice we provide will be based on and take into account a majority of product types and not every single equivalent product within a given product category. As such, our advice is restricted (as opposed to independent) as defined by the Financial Conduct Authority (“FCA”).
6. Changes in the rates of exchange between currencies may cause the value of investments to go up or down in the reporting currency. Returns may increase or decrease as a result of currency fluctuations. Values may also be affected by developments relating to controls and restrictions on foreign currency remittance of proceeds of investments in a non-sterling jurisdiction.
7. Whilst every effort is made to ensure that the information provided to clients is accurate and up to date, some of the information may be rendered inaccurate by changes in applicable laws and regulations. For example, the levels and bases of taxation may change.
8. The material contained in this document is not to be regarded as an offer to buy or sell or the solicitation of any offer to buy or sell securities in any jurisdiction where such an offer or solicitation is against the law, or to anyone to whom it is unlawful to make such an offer or solicitation, or if the person making the offer or solicitation is not qualified to do so. The information on this document does not constitute legal, tax, or investment advice. You must not, therefore, rely on the content of this document when making any investment decisions.

In addition to the information provided by Stonehage Fleming Investment Management Limited you may wish to consult an independent professional.

This communication has been approved for distribution in South Africa and those countries of the EEA where distribution is permitted by:

Stonehage Fleming Investment Management Limited
15 Suffolk Street
London SW1Y 4HG

Stonehage Fleming Investment Management Limited is authorised and regulated by the Financial Conduct Authority and registered with the Financial Sector Conduct Authority (South Africa) as a Financial Services Provider (“FSP”) FSP No: 46194.

